Compare Keysight Technologies Inc (KEYS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Eli Lilly And Co — how do they compare? Keysight Technologies Inc trades at $382.61 (market cap $63.79B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 16.3× Keysight Technologies Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Eli Lilly And Co for 93 Days on average.
| KEYS | LLY | |
|---|---|---|
Market Cap | $63.79B | $1.04T |
Volume | 1,435,384 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $387.90 | $1.28K |
52-Week Low | $159.49 | $799.57 |
Typical Hold Time | 56 Days | 93 Days |
Enterprise Value | $63.93B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.61, up 0.29% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with accelerating earnings, beating estimates for three consecutive quarters, and impressive profitability metrics including 19.14% net income margin and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, positioning the company for continued growth.
KEYS presents a compelling investment case with strong analyst consensus (81% buy ratings) and a $416.63 price target offering 8.9% upside. However, elevated valuation ratios (P/E 50.7, P/S 9.85) and supply chain constraints present near-term risks. The company's leadership in AI testing and 6G technology provides long-term growth catalysts despite current premium pricing.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
